Edwards Lifesciences Corp (EW) VP Sells $762,300.00 in Stock

Edwards Lifesciences Corp (NYSE:EW) VP Larry L. Wood sold 6,300 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $121.00, for a total transaction of $762,300.00. Following the completion of the sale, the vice president now directly owns 116,148 shares of the company’s stock, valued at $14,053,908. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Larry L. Wood also recently made the following trade(s):

  • On Friday, December 15th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences stock. The shares were sold at an average price of $114.58, for a total transaction of $2,172,436.80.
  • On Wednesday, November 15th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences stock. The shares were sold at an average price of $104.76, for a total transaction of $1,986,249.60.

Edwards Lifesciences Corp (NYSE:EW) traded up $0.42 during trading hours on Wednesday, hitting $120.49. 1,176,088 shares of the stock traded hands, compared to its average volume of 1,410,000. Edwards Lifesciences Corp has a twelve month low of $86.55 and a twelve month high of $122.93. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.76 and a current ratio of 3.49. The company has a market cap of $25,500.00, a price-to-earnings ratio of 35.03, a P/E/G ratio of 1.93 and a beta of 0.51.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the consensus estimate of $0.86 by ($0.02). Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The business had revenue of $821.50 million during the quarter, compared to the consensus estimate of $833.85 million. During the same quarter in the prior year, the firm posted $0.68 EPS. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. sell-side analysts expect that Edwards Lifesciences Corp will post 3.76 EPS for the current fiscal year.

Edwards Lifesciences announced that its board has approved a stock repurchase plan on Thursday, December 7th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Several equities research analysts have issued reports on EW shares. Cowen set a $135.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Sunday, December 10th. JPMorgan Chase & Co. cut shares of Edwards Lifesciences from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. SunTrust Banks set a $124.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Morgan Stanley lowered their price objective on shares of Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating for the company in a research report on Thursday, October 26th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $137.00 price objective on shares of Edwards Lifesciences in a research report on Friday, December 8th. Six analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $129.57.

Several large investors have recently bought and sold shares of EW. Profund Advisors LLC raised its holdings in shares of Edwards Lifesciences by 7.3% in the 2nd quarter. Profund Advisors LLC now owns 9,342 shares of the medical research company’s stock valued at $1,105,000 after purchasing an additional 639 shares in the last quarter. Artisan Partners Limited Partnership raised its holdings in shares of Edwards Lifesciences by 90.6% in the 2nd quarter. Artisan Partners Limited Partnership now owns 1,278,532 shares of the medical research company’s stock valued at $151,174,000 after purchasing an additional 607,784 shares in the last quarter. New York State Common Retirement Fund raised its stake in shares of Edwards Lifesciences by 10.4% during the 2nd quarter. New York State Common Retirement Fund now owns 509,200 shares of the medical research company’s stock worth $60,208,000 after acquiring an additional 47,799 shares in the last quarter. UBS Asset Management Americas Inc. raised its stake in shares of Edwards Lifesciences by 6.4% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 611,062 shares of the medical research company’s stock worth $72,252,000 after acquiring an additional 36,936 shares in the last quarter. Finally, Ithaka Group LLC raised its stake in shares of Edwards Lifesciences by 1.0% during the 2nd quarter. Ithaka Group LLC now owns 133,902 shares of the medical research company’s stock worth $15,833,000 after acquiring an additional 1,290 shares in the last quarter. Institutional investors and hedge funds own 81.61% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Edwards Lifesciences Corp (EW) VP Sells $762,300.00 in Stock” was first posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/01/17/edwards-lifesciences-corp-ew-vp-sells-762300-00-in-stock.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply